Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early ustekinumab after steroid-induced remission in moderate-to-severe ulcerative colitis
2021-001984-25Phase 2Terminated
- Sponsor
- ASST Sette Laghi
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ustekinumab in autoimmune colitis, sponsored by ASST Sette Laghi. Primary endpoint: Endoscopic remission at 54 weeks. Started Jan 2022; status: terminated.
02
Drugs
ustekinumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2021-001984-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001984-25.